Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 161 publications
Optimizing Radiography Utilization: Multidisciplinary Expert Consensus Recommendations Endorsed by the Society of Academic Bone Radiologists, Society of Skeletal Radiology, American Society of Emergency Radiology, Orthopaedic Trauma Association, American Academy of Emergency Medicine, and American Rhinologic Society.
Journal: Radiology
Published: May 19, 2026
Neural Network Machine Learning for Determining Surgical Appropriateness in Head and Neck Subspecialty Referrals.
Journal: Ear, nose, & throat journal
Published: April 08, 2026
Post-Radiation Dental Care Access Among Head and Neck Cancer Survivors: A Safety Net Perspective.
Journal: Laryngoscope investigative otolaryngology
Published: March 30, 2026
ASO Visual Abstract: Key Updates on the Version 9 AJCC/UICC Staging System for Salivary Gland Carcinoma.
Journal: Annals of surgical oncology
Published: March 26, 2026
Prevalence of High-Risk Human Papillomavirus and Associated Risk Factors Among Individuals With Head and Neck Cancer in a National Referral Center in Tanzania.
Journal: JCO global oncology
Published: March 17, 2026
Neutrophil-To-Lymphocyte Ratio and Survival in Pembrolizumab-Treated Oropharyngeal Cancer.
Journal: Head & neck
Published: February 24, 2026
Proposed Version Nine of the AJCC and UICC TNM Classification for Salivary Gland Carcinoma.
Journal: JAMA otolaryngology-- head & neck surgery
Published: February 12, 2026
Key Updates on the Version 9 AJCC/UICC Staging System for Salivary Gland Carcinoma.
Journal: Annals of surgical oncology
Published: January 26, 2026
Economic Impact of a Deep Learning Algorithm for Automated Head and Neck Surgery Referral Triage.
Journal: The Laryngoscope
Published: December 16, 2025
Perineural Invasion and Survival in Pembrolizumab-Treated Head and Neck Squamous Cell Carcinoma.
Journal: The Laryngoscope
Published: November 20, 2025
Potent Anti-Tumor Activity of the AXL-Targeted Antibody-Drug Conjugate, Mipasetamab Uzoptirine (ADCT-601), in Preclinical Models of Adenoid Cystic Carcinoma.
Journal: Molecular cancer therapeutics
Published: November 04, 2025
Potent anti-tumor activity of the AXL-targeted antibody-drug conjugate, mipasetamab uzoptirine (ADCT-601), in preclinical models of adenoid cystic carcinoma.
Journal: Molecular cancer therapeutics
Published: November 04, 2025
Last Updated: 09/26/2026